Dipak Kotecha (Institute of Cardiovascular Sciences, University of Birmingham) discusses the FAST trial – the first long-term follow-up of a randomised trial comparing thoracoscopic surgical atrial fibrillation ablation with catheter ablation with the aim of rhythm control. Thoracoscopic ablation is a more surgical procedure with a dedicated atrial fibrillation surgeon who makes thoracoscopy ports and then can inspect the heart and do epicardial atrial fibrillation ablation outside of the heart. At the same time, they can do additional lines that cannot be done by electrophysiologists and can isolate the left atrial appendage. Both arms of the trial evidenced a sharp recurrence of atrial fibrillation, but over time the thoracoscopic patients did a lot better in terms of less atrial arrhythmia, less use of anti-arrhythmic drugs, and less additional procedures required whereas three quarters of the patients who received catheter ablation redeveloped some form of atrial arrhythmia over the seven years of follow-up.
Filmed at EHRA 2018, Barcelona.
1. What was the background and rationale behind the FAST trial? 0:07
2. What were the key results you presented at this meeting? 0:25
3. What are the next steps in this area of research over the coming years? 2:45
4. What are the practical implications and challenges? 3:53
Share this Video
Related Videos In Interventional Cardiology
David Keane, AF Symposium 2021: Challenges in Catheter Ablation
We spoke to Professor David Keane (St Vincent’s University Hospital, Dublin, Ireland) about the current challenges procedural duration and overall success in catheter ablation, and the most exciting innovations to aim to overcome these. Questions: What are the current challenges in catheter ablation in terms of procedural duration and overall success? (0.13) What are the […]
David Keane, AF Symposium 2021: Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy
We spoke to Professor David Keane (St Vincent’s University Hospital, Dublin, Ireland) about atrial fibrillation in patients with hypertrophic cardiomyopathy. Questions: What is the incidence of atrial fibrillation (AF) in people with hypertrophic cardiomyopathy (HCM)? (0.13) What is known about the efficacy and safety of catheter ablation of AF in patients with HCM compared to […]
Andrea Natale, AF Symposium 2021: Impact of Catheter Ablation on Quality of Life and Health Care Utilization
We spoke to Dr Andrea Natale (Texas Cardiac Arrhythmia Institute, Austin, TX, USA) about the most exciting recent innovations in catheter ablation technology. Questions: What is the impact of atrial fibrillation (AF) ablation on healthcare utilization and quality of life? (0.13) How should these data influence the timing of ablation strategies? (2.40) Speaker disclosures: Dr […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!